Changes reporter's name; no changes to text
May 25 (Reuters) - ** Divi's Laboratories DIVI.NS posted 13.4% Y/Y rise in Q4 consol profit, on strong performance in the custom synthesis and nutraceuticals segments
** Shares of pharmaceuticals co down 1.6%
SUB-HEAD
** Jefferies ("buy," PT: 7,950 rupees) management was
uncertain regarding margin outlook as dedicated capacities are being built up using technology owned by innovator and it is yet to receive commercial quantities
** BOB Capital Markets ("hold," PT: 7,500 rupees) says margin headwinds to persist in near term
** Ambit Capital ("sell," PT: 6,230 rupees) cuts EBITDA estimates by ~4% citing near-term gross margin pressure and change in revenue mix
** Dolat Capital ("reduce," PT: 6,942 rupees) says co faced difficulty in sourcing raw materials during March quarter due to the West Asia war but managed through domestic suppliers
** Systematix ("hold," PT: 6,539 rupees) says drop
in gross margin in Q4 was despite a favorable currency movement and favorable business mix
(Reporting by Vijay Malkar in Bengaluru)
((VijayDattaram.Malkar@thomsonreuters.com; Mobile: +91 8097833031;))